Brief: Cingulate Completes First Cohort Of Phase 3 Adult Onset And Duration Trial Of Ctx-1301 (Dexmethylphenidate) For Adhd

Cingulate

04/04/2023 12:17

April 4 (Reuters) - Cingulate Inc  CING.O :
    * CINGULATE COMPLETES FIRST COHORT OF PHASE 3 ADULT ONSET
AND
DURATION TRIAL OF CTX-1301 (DEXMETHYLPHENIDATE) FOR ADHD
    * CINGULATE INC - PIVOTAL PHASE 3 TRIAL IN
PEDIATRIC/ADOLESCENT
PATIENTS PLANNED TO BEGIN MID-2023
    * CINGULATE INC - CTX-1301 TRIAL ON TRACK FOR 3Q 2023
RESULTS
    * CINGULATE INC : PLANS TO SUBMIT NDA FOR CTX-1301 IN FIRST
HALF
OF 2024

Source text for Eikon:  ID:nGNX3HWnL9 
Further company coverage:  CING.O 

 ((reuters.briefs@thomsonreuters.com;))